Related Experiment Video
Updated: Oct 27, 2025
Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis
Published on: September 26, 2022
Serum Contactin-1 in CIDP: A Cross-Sectional Study
Luuk Wieske1, Lorena Martín-Aguilar2, Janev Fehmi2
1From the Department of Neurology and Neurophysiology (L.W., C.V., F.E.), Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands; Neuromuscular Diseases Unit (L.M.-A., C.L., L.Q.), Department of Neurology, Hospital de La Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Department of Clinical Neurosciences (J.F., S.R.), West Wing, John Radcliffe Hospital, Oxford, United Kingdom; Neurochemistry Lab (M.J.A.K.-S., C.E.T.), Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; and Department of Neurology (M.C., Z.L., J.K.), Amsterdam Neuroscience, Amsterdam UMC, Location VU Medical Center, Amsterdam, the Netherlands. l.wieske@amsterdamumc.nl.
Serum contactin-1 levels may help diagnose paranodal injury in chronic inflammatory demyelinating polyneuropathy (CIDP). Lower levels indicate paranodal antibodies, suggesting contactin-1 as a potential biomarker for this condition.
Area of Science:
- Neurology
- Immunology
- Biomarker Discovery
Background:
- Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder affecting peripheral nerves.
- Paranodal injury, a specific type of nerve damage, is implicated in some CIDP cases.
- Identifying reliable biomarkers for paranodal injury in CIDP is crucial for diagnosis and management.
Purpose of the Study:
- To determine if serum contactin-1 levels correlate with paranodal injury in CIDP patients.
- To investigate contactin-1 as a potential diagnostic biomarker for CIDP with paranodal antibodies.
Main Methods:
- Serum contactin-1 levels were quantified in 187 CIDP patients and 222 healthy controls.
- Presence of paranodal antibodies was assessed in all CIDP patients.
- Statistical analysis, including ROC curve analysis, was performed to evaluate diagnostic performance.
Main Results:
- Serum contactin-1 levels were significantly lower in CIDP patients with paranodal antibodies (N=41) compared to those without (N=146).
- The area under the curve (AUC) for discriminating between these groups was 0.84, indicating good diagnostic accuracy.
- Sensitivity was 71% and specificity was 97% for identifying CIDP patients with paranodal antibodies.
Conclusions:
- Serum contactin-1 levels show potential as a diagnostic biomarker for paranodal injury in CIDP.
- Contactin-1 can effectively discriminate between CIDP patients with and without paranodal antibodies.
- This study provides class II evidence supporting the utility of serum contactin-1 in CIDP diagnostics.
